UroGen Pharma Ltd. — Director's Dealing 2024

Sep 12, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2024-09-09

Reporting Person: Smith Jason Drew (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-09	Ordinary Shares	M	3333	—	Acquired	26747	Direct
2024-09-09	Ordinary Shares	S	1521	$13.08	Disposed	25226	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-09-09	Restricted Stock Units	$	M	3333	Disposed		Ordinary Shares (3333)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.